<DOC>
	<DOCNO>NCT01386723</DOCNO>
	<brief_summary>This study propose observe whether stable platelet count would maintain without additional treatment long term least proportion patient discontinue eltrombopag take least 4 month . This require patient stop treatment eltrombopag , immediately transition treatment unless necessary . The objective study ass frequently patient discontinue eltrombopag attain stable , treatment-free , unmaintained adequate platelet count 4 8 week discontinue eltrombopag long response last ( occurs ) .</brief_summary>
	<brief_title>End EXTEND : Discontinuation Medication Patients With Immune Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>A subject eligible study entry follow criterion apply : Subject guardian sign date write informed consent Male female adult ( â‰¥ 18 year ) diagnose ITP accord new consensus guideline No indication disease may cause thrombocytopenia ITP . Having take eltrombopag least 4 month prior begin study . Subject experience toxicity transient eltrombopagrelated toxicity drug intolerance . Subjects treat concomitant ITP medication ( e.g . corticosteroid azathioprine ) must receive dose stable least four week prior start study . A subject practicing acceptable method contraception ( documented chart ) . female subject female partner male subject must either nonchild bear potential ( hysterectomy , bilateral ovariectomy , bilateral tubal ligation post menopausal one year ) OR child bear potential use one follow highly effective method contraception . complete abstinence intercourse Intrauterine device ( IUD ) Two form barrier contraception . diaphragm plus spermicide , male condom plus spermicide . Male partner sterile partner female . Systemic contraceptive ( combined oral progesterone ) A subject least temporarily ineligible study follow criterion apply : Any clinically relevant abnormality , chronic ITP , identify screen examination , medical condition circumstance , opinion investigator make subject unsuitable participation study : active malignancy arterial venous thrombosis development grade IIIIV cardiovascular disease ( include congestive heart failure , New York Heart Association ( NYHA Grade III/IV ) , arrhythmia know increase risk thromboembolic event ( e.g . atrial fibrillation ) , subject QTc &gt; 480 msec . Recent history alcohol/drug abuse . Subjects recently treat drug affect platelet function ( include limit aspirin , clopidogrel and/or NSAIDs ) anticoagulants &gt; 3 consecutive day within 2 week study start end study . development platelet agglutination abnormality prevents reliable measurement platelet count . Rescreening possible condition result fail screen resolve . There limit number screen test screen valid 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>eltrombopag</keyword>
	<keyword>promacta</keyword>
	<keyword>immune thrombocytopenia ( ITP )</keyword>
</DOC>